Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2002

View Archived Issues

Promising early clinical results for dexosome vaccine in melanoma

Clinical data on the proteasome inhibitor PS-341 in multiple myeloma updated

Influence of renal dysfunction on safety profile of pemetrexed

Pharmacokinetics of epothilone B assessed in patients with advanced cancer

Tadalafil reported safe and effective in broad-spectrum erectile dysfunction

No beneficial effects found for nutritional supplementation in fibromyalgia

Preliminary data suggest potential for pramipexole in fibromyalgia

Potential use of pregabalin in fibromyalgia

Novel mu-selective opioid ligand identified at Purdue Pharma

Dyax and Thios enter therapeutic antibody discovery and development collaboration

Chemokine CCR2 and/or CCR3 antagonists under study at Pfizer

Ferring and Johnson & Johnson to develop new generation of type 2 diabetes drugs

NeuroSearch claims modulators of monoamine receptors and transporters with broad applications

Prodrug-based antiinfectives objective of Ricerca and ProQuest collaboration

Novel HIV reverse transcriptase inhibitors in Medivir pipeline

Pharmacia researchers describe new CDK inhibitors for cancer and other indications

Progen receives clearance to begin PI-166 clinical trial

Servier and ConjuChem report novel albumin-binding metalloproteinase inhibitors

Serono and Ivax to develop and commercialize oral cladribine for MS

Novartis to sell Leucomax rights to Schering-Plough

Oryx to market Angiomax in Canada

Replagal E.U. labeling expanded to include treatment of females

Potential for OPC-14523 in bulimia nervosa and OCD

Novel mglu5 receptor antagonists as potential anxiolytic agents

Anxiolytic profile of PNU-57378E evaluated in rodent models

Novartis acquires rights to AGE breaker from Torrent

SuperGen to begin Orathecin NDA submission by year-end 2002

Biovail receives tentative FDA approval for Flash Dose zolpidem

Pravachol approved for use in pediatric patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.